JADE 001
Alternative Names: JADE-001Latest Information Update: 03 Feb 2025
Price :
$50 *
At a glance
- Originator Paragon Therapeutics
- Developer Jade Biosciences
- Class Monoclonal antibodies
- Mechanism of Action Tumour necrosis factor ligand superfamily member 13 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical IgA nephropathy
Most Recent Events
- 31 Oct 2024 Paragon Therapeutics files provisional patent applications covering the subject matter of JADE 001 before October 2024
- 31 Oct 2024 Preclinical trials in IgA nephropathy in USA (Parenteral) before October 2024
- 31 Oct 2024 Jade Biosciences plans a first-in-human clinical trial for IgA nephropathy (Parenteral) in second half of 2025